Nan Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nan Cheng has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Visekruna
Institute for Medical Microbiology and Hygiene Philipps‐University Marburg Marburg Germany
1 shared publication Anthony Federico
Division of Computational Biology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America
1 shared publication- Eleni Stampouloglou
Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts, United States of America
1 shared publication - Emily M. Slaby
Chemical, Biochemical, and Environmental Engineering, University of Maryland Baltimore County, Baltimore, MD, United States
1 shared publication - Gregory Lee Szeto
Allen Institute for Immunology
1 shared publication Hanna Leister
Institute for Medical Microbiology and Hygiene Philipps‐University Marburg Marburg Germany
1 shared publication
Latest Publications
- Open Access
- 25 July 2022
- Published by Wiley in European Journal of Immunology
- Vol. 52 (9) , 1523-1526
Verteporfin protects against Th17 cell‐mediated EAE independently of YAP inhibition
The known YAP inhibitor verteporfin is capable of repressing IL-17A production in Th17 cells. However, this effect is mediated independently of YAP and can ameliorate Th17-mediated experimental autoimmune encephalomyelitis (EAE) upon in vivo administration. The data suggest verteprofin's mode of action for the design of novel therapeutic autoimmune disease intervention.
- 25 July 2022
- Published by Wiley in European Journal of Immunology
- Vol. 52 (9) , 1523-1526
Open AccessVerteporfin protects against Th17 cell‐mediated EAE independently of YAP inhibition
The known YAP inhibitor verteporfin is capable of repressing IL-17A production in Th17 cells. However, this effect is mediated independently of YAP and can ameliorate Th17-mediated experimental autoimmune encephalomyelitis (EAE) upon in vivo administration. The data suggest verteprofin's mode of action for the design of novel therapeutic autoimmune disease intervention.
- Open Access
- 13 January 2020
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 18 (1) , e3000591
Yap suppresses T-cell function and infiltration in the tumor microenvironment
A major challenge for cancer immunotherapy is sustaining T-cell activation and recruitment in immunosuppressive solid tumors. Here, we report that the levels of the Hippo pathway effector Yes-associated protein (Yap) are sharply induced upon the activation of cluster of differentiation 4 (CD4)-positive and cluster of differentiation 8 (CD8)-positive T cells and that Yap functions as an immunosuppressive factor and inhibitor of effector differentiation. Loss of Yap in T cells results in enhanced T-cell activation, differentiation, and function, which translates in vivo to an improved ability for T cells to infiltrate and repress tumors. Gene expression analyses of tumor-infiltrating T cells following Yap deletion implicates Yap as a mediator of global T-cell responses in the tumor microenvironment and as a negative regulator of T-cell tumor infiltration and patient survival in diverse human cancers. Collectively, our results indicate that Yap plays critical roles in T-cell biology and suggest that Yap inhibition improves T-cell responses in cancer.
- 13 January 2020
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 18 (1) , e3000591
Open AccessYap suppresses T-cell function and infiltration in the tumor microenvironment
A major challenge for cancer immunotherapy is sustaining T-cell activation and recruitment in immunosuppressive solid tumors. Here, we report that the levels of the Hippo pathway effector Yes-associated protein (Yap) are sharply induced upon the activation of cluster of differentiation 4 (CD4)-positive and cluster of differentiation 8 (CD8)-positive T cells and that Yap functions as an immunosuppressive factor and inhibitor of effector differentiation. Loss of Yap in T cells results in enhanced T-cell activation, differentiation, and function, which translates in vivo to an improved ability for T cells to infiltrate and repress tumors. Gene expression analyses of tumor-infiltrating T cells following Yap deletion implicates Yap as a mediator of global T-cell responses in the tumor microenvironment and as a negative regulator of T-cell tumor infiltration and patient survival in diverse human cancers. Collectively, our results indicate that Yap plays critical roles in T-cell biology and suggest that Yap inhibition improves T-cell responses in cancer.